Is the Price Right for Absorb Scaffold? Expenses similar to Xience, but adverse events could impact long-term cost-effectiveness
The Absorb bioresorbable vascular scaffold — under FDA investigation in the U.S. and limited to registry use in Europe due to adverse events — wasn’t substantially more expensive than durable drug-eluting stents (DES) when used for percutaneous coronary intervention (PCI) in certain patients, an economic substudy of ABSORB III found.